Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(4.02)
# 591
Out of 4,653 analysts
92
Total ratings
61.7%
Success rate
9.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Neutral | $70 → $80 | $92.63 | -13.63% | 9 | Nov 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $494.61 | -2.95% | 19 | Nov 5, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $110 → $90 | $66.66 | +35.01% | 13 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $804.33 | +26.19% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $301.44 | +34.36% | 2 | Oct 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $50 | $58.41 | -14.40% | 8 | Oct 18, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $264.60 | -16.86% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $8.28 | +20.77% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $6.96 | -6.61% | 4 | May 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Initiates: Overweight | $72 | $49.79 | +44.61% | 1 | Apr 13, 2023 |
Gilead Sciences
Nov 7, 2024
Maintains: Neutral
Price Target: $70 → $80
Current: $92.63
Upside: -13.63%
Vertex Pharmaceuticals
Nov 5, 2024
Reiterates: Overweight
Price Target: $480
Current: $494.61
Upside: -2.95%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $90
Current: $66.66
Upside: +35.01%
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $804.33
Upside: +26.19%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $301.44
Upside: +34.36%
Bristol-Myers Squibb Company
Oct 18, 2024
Reiterates: Neutral
Price Target: $50
Current: $58.41
Upside: -14.40%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $264.60
Upside: -16.86%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $8.28
Upside: +20.77%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $6.96
Upside: -6.61%
CRISPR Therapeutics AG
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $49.79
Upside: +44.61%